BioSight
Companies
COMPASS Pathways plc logo

CMPS

NASDAQCHESIRE, X0
COMPASS Pathways plc

COMPASS Pathways develops COMP360, a psilocybin-based treatment for mental health conditions including treatment-resistant depression and post-traumatic stress disorder. The company is in clinical-stage development, currently running Phase 3 trials for treatment-resistant depression and a Phase 2b/3 trial for PTSD, with plans to submit a new drug application to the FDA.

Price history not yet available for CMPS.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar